Old Web
English
Sign In
Acemap
>
Paper
>
P530 Cost-effectiveness of vedolizumab SC vs. adalimumab for moderately to severely active ulcerative colitis
P530 Cost-effectiveness of vedolizumab SC vs. adalimumab for moderately to severely active ulcerative colitis
2020
I. Diakité
B Schultz
John A. Carter
Sonya J. Snedecor
Robin S. Turpin
Keywords:
Golimumab
Physical therapy
Ulcerative colitis
Tofacitinib
Gastroenterology
Adalimumab
Vedolizumab
Randomization
Diabetes mellitus
Internal medicine
Medicine
Infliximab
cost effectiveness
treatment outcome
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]